Avalyn Pharma officer proposes $1.58M stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avalyn Pharma Inc. (AVLN) officer Howard Lazarus reported a proposed sale of 53,200 common shares, with an aggregate market value of $1,583,232 and an approximate sale date of November 17, 2026. Lazarus's remarks state that the shares were and will be received upon exercise of stock options over the next three months, and list July 30, 2026, as the Rule 10b5-1 plan adoption date.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is Howard Lazarus's proposed AVLN sale tied to a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.